Eradicating the use of
Antibiotics Globally

20 years of Peptide Scientific R&D Catalysed by AI replacing antibiotics globally

Bio-Organic

Sustainable solutions powered by advanced peptide platforms.

Mission Statement

PHYTOCYTE’s mission is using Ai to build on 10 years of scientific research developing advanced Anti Microbial Peptides and next-generation biotechnology to replace the use of anti biotics in the global food, and animal health food chains We design development strategies that eradicate the need for in-feed antibiotics enhance animal health, and reduce antibiotic dependency across aquaculture, agriculture, and livestock production systems.

Our technology integrates optimization of structural parameters, sequence modification, and nano-delivery systems to deliver scalable, safe, and effective alternatives that protect ecosystemsand reinforce global food security

Within 10 years we anticipate developing anti microbial peptides to replace the use of anti biotics for human use. .

Antimicrobial peptides

Animal health

Replace antibiotics

Food security

Strategic Objective

To commercialise PHYTOCYTE technology and establish it as trusted, science-driven partner in global animal health and the worlds food chain

Innovate

Advance peptide platform for targeted anti-microbial solutions.
Develop precision cannabinoid extraction and application protocols.

Scale

Expand commercial trials across poultry, livestock, and agriculture.
Implement high-efficiency production frameworks for global supply.

Expand

Establish strategic footprints across Asia-Pacific and North America.
Pursue international capital market listings and partnerships.

Phytocyte Pty Ltd

PhytoCyte is an emerging biosciences company developing a new generation of Anti-Microbial Peptides (AMPs), designed to address the growing global demand for alternatives to traditional antibiotics. The company has already demonstrated successful applications in aquaculture and is now progressing into veterinary trials for poultry and livestock, while expanding into food preservation, disinfectants, agriculture, and future human health applications.

In parallel, PhytoCyte is building a broader biotechnology platform through strategic acquisitions and advanced cannabinoid technologies developed for laboratory production. Through a proposed transaction with Bakhu Holdings Company, PhytoCyte aims to establish a globally focused bioscience and technology group with planned expansion across Asia-Pacific and international capital markets. The group is currently advancing multiple acquisition opportunities in Hong Kong, Singapore, and Australia, while pursuing an uplisting strategy toward NASDAQ to support long-term growth, liquidity, and global investor access.

Our Services

We are developing new technologies to eliminate the use of antibiotics in the control of diseases affecting aquaculture, agriculture, and human health and wellness.